53976-62-8

Basic information

• Product Name: 2,5-Dichloro-pyridine 1-oxide
• Synonyms: 2,5-Dichloro-pyridine 1-oxide;2,5-Dichloro-1-oxido-pyridin-1-ium
• CAS NO: 53976-62-8
• Molecular Formula: C₅H₃Cl₂NO
• Molecular Weight: 163.98942
• EINECS: -0
• Mol File: 53976-62-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 73-75 °C
• Boiling Point: 340.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.47±0.1 g/cm3(Predicted)
• PKA: -1.49±0.10(Predicted)
• CAS DataBase Reference: 2,5-Dichloro-pyridine 1-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dichloro-pyridine 1-oxide(53976-62-8)
• EPA Substance Registry System: 2,5-Dichloro-pyridine 1-oxide(53976-62-8)

Safety Data

• Hazardous Substances Data: 53976-62-8(Hazardous Substances Data)

Usage

Description

2,5-Dichloro-pyridine 1-oxide is a chemical compound with the molecular formula C5H3Cl2NO. It is a pale yellow to white crystalline solid that is highly reactive and known for its ability to undergo nucleophilic substitution reactions.
Used in Pharmaceutical Industry:
2,5-Dichloro-pyridine 1-oxide is used as a key intermediate in the synthesis of various pharmaceuticals. Its reactivity allows for the creation of a wide range of drug molecules, making it a valuable component in the development of new medications.
Used in Agrochemical Industry:
2,5-Dichloro-pyridine 1-oxide is also utilized in the production of agrochemicals, contributing to the development of pesticides and other agricultural products that help protect crops and enhance yields.
Used in Dye and Pigment Manufacturing:
2,5-Dichloro-pyridine 1-oxide is used in the manufacturing of dyes and pigments, where its chemical properties enable the production of a variety of colorants for different applications.
Safety Note:
It is important to handle 2,5-Dichloro-pyridine 1-oxide with care due to its toxicity and potential to cause irritation to the skin, eyes, and respiratory system if not properly managed.

Upstream product

• 16110-09-1 2,5 dichloropyridine 

Downstream Products

• 405230-81-1 2,5-dichloro-4-nitropyridine-1-oxide 
• 163152-53-2 3-chloro-3-deazaadenosine 
• 405230-94-6 3,4-diamino-2,5-dichloropyridine 
• 405230-91-3 4-amino-2,5-dichloro-3-nitropyridine 
• 405231-09-6 4,7-dichloro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 1702-18-7 3,6-dichloro-2-pyridinecarbonitrile 
• 869886-90-8 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1H pyrrole-2-carboxylic acid 
• 869886-89-5 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1-(2,4,6-trimethylbenzenesulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 869886-92-0 4-(5-chloro-2-isopropylamino-pyridin-4-yl)-1-(2,4,6-trimethyl-benzenesulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester N-oxide 

Relevant articles and documents

PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Benzimidazole and pyridylimidazole derivatives

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.

Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents

Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogensubstituted analogues (51 and 52), and 2′,3′ -dihalogen- substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7μM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.